Investigational Bifidobacterium Preparation MR-61

Phase 2Biologic

SSecond Affiliated Hospital of Nanchang University

Investigational Bifidobacterium Preparation MR-61 is one of 22 biologic programs targeting Myopia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyopiaActive, not recruiting

MyopiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

58 competitors in Myopia

#DrugCompanyPhaseTrials

Atropen

FFresenius Kabi Oncology Ltd.

Approved

12 2

Alphagan

Isopto Carpine

Mitosol

Oxylone

1 6

Lucentis

Lotemax

1 8

Mydriacyl

FFalcon

Approved

1 9

Avastin

BBio-Thera Solutions

Phase 3

—10

Carboxymethylcellulose

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Myopia

NCT07298824

Clinical

Trials by Indication[1]

Myopia1 trial

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia

Recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT07298824·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Investigational Bifidobacterium Preparation MR-61. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigational Bifidobacterium Preparation MR-61 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigational Bifidobacterium Preparation MR-61. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Nanchang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital of Nanchang University

Investigational Bifidobacterium Preparation MR-61

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Myopia1 trial

References

Drug Info

Quick Facts

Related News